As EGFR is a potential therapeutic target for TNBC, EGFR-specific CAR NK cells (EGFR-CAR NK cells) is a promising strategy to inhibit tumor growth in breast cancer cell line-derived xenograft (CLDX) and patient-derived xenograft (PDX) mouse models (62). The gene discussed is EGFR; the disease is breast carcinoma.